secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0000950170-22-002956
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks
--------------------------------------------------------------------

- KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.
- Trial is double-blind, placebo-controlled, crossover; two doses (300 mg, 600 mg) vs placebo.
- Primary endpoint: time to beginning of symptom relief per Patient Global Impression of Change (PGI-C) scale.
- Enrollment: minimum 84 adolescent and adult patients at ~60 sites in 20 countries.
- Top-line data expected in second half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/0000950170-22-002956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022002956/kalv-20220307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer